Given the importance of immune effector cell function in combating cancer, and the increasing adoption of immunotherapies in solid tumour treatment, immune-sparing, α-specific PI3K inhibition is likely preferable to pan-PI3K isoform inhibition. This evidence concerns the gene PIK3CB and cancer.